Trial Design
We conducted this phase 3 trial (DAWN) from Oct 11, 2017 to Aug 31, 2020 at 73 sites in China, in Chinese type 2 diabetes patients with insufficiently controlled blood glucose on metformin. The DAWN trial included a 2-week screening period, a 4-week single-blind run-in period, a 24-week double-blind placebo-controlled treatment period followed by an extended 28-week open-label treatment period, and a 1-week follow-up period (Fig. 1a). During the single-blind placebo run-in period, patients were treated with metformin at 1500 mg per day as basic therapy. Patients were randomly assigned in a 1:1 ratio to receive either dorzagliatin twice a day plus daily metformin (1500 mg) or placebo twice a day plus daily metformin (1500 mg) for a 24-week double-blind period, on a background of a diet and exercise regimen. Then all patients received dorzagliatin twice a day plus daily metformin (1500 mg) treatment for a 28-week open-label period. During the open-label period, patients assigned to dorzagliatin plus metformin continued their treatment unchanged, whereas those assigned to placebo plus metformin switched from the placebo to dorzagliatin plus metformin. After the 52-week treatment, all patients were observed for 1 week for safety evaluation.
Patients were recruited at the study site by investigators. Patients were required to sign the informed consent form before enrollment. After providing written informed consent, patients were screened for eligibility. Patients who were 18 to 75 years of age, diagnosed with type 2 diabetes, and on diet and exercise interventions, who were receiving stable daily doses of metformin (1500 mg per day at minimum) at least 12 weeks before screening, and who had a HbA1c level of 7.5 to 10.0%, and a body-mass index of 18.5 to 35.0 kilogram per square meters at screening were eligible for enrollment. Key exclusion criteria were any previous antidiabetic treatment other than metformin within 12 weeks, previous insulin treatment for more than 30 days within 1 year before screening, severe hypoglycemia without cause within 3 months, or frequent hypoglycemia occurred more than 3 times within 1 month before screening, fasting C-peptide level of less than 0.81 ng per milliliter at screening, and a history of type 1 diabetes. Other exclusion criteria were the major cardio-cerebrovascular diseases within 6 months before screening; unstable or rapidly progressive kidney disease; active liver diseases; psychiatric disease; any type of malignancy; an alanine or aspartate transaminase level 2.5 times greater than the upper limit of the normal range, or serum total bilirubin level 1.5 times greater than the upper limit of the normal range; eGFR<60 ml/min/1.73m2 at screening. Complete lists of inclusion, exclusion, and randomization criteria are provided in the protocol, available in the supplemental material.
PrOCEDURES
At week 3 in the 4-week run-in period, patients were evaluated before randomization to confirm the eligibility. Eligibility criteria included a HbA1c level of 7.5 to 10.0%, and a fasting plasma glucose level of 7.0 to 13.3 mmol per liter (126 to 239 mg/dl) at randomization. Diet and exercise counseling was provided during the entire experiment. Randomization and drug dispense were performed with an interactive web response system (IWRS) (Balance, MedData Solution). The random allocation sequences were generated by the IWRS. A stratified randomization method with the permuted block randomization algorithm was used. The blocks were dynamically allocated to each site and stratum from the randomization list. A unique identification number (drug box serial number) was provided by the study medication packing provider and marked on the label of drug box. By central randomization, the randomization codes were generated by IWRS system based on randomization factors (T2DM disease duration ≤ 3 years or > 3 years and HbA1c level ≤ 8.5% or > 8.5% at randomization) and the block size. Then, the randomization codes along with the corresponding drug box numbers were provided to subjects who meet the randomization criteria at each visit.
Investigators enrolled participants and used IWRS to assign participants to interventions. Double-blind method was used in the study. The random allocation sequences were concealed from patients, investigators and all other study members. Placebo tablets were designed with the size, color, smell and appearance same as the active drug tablets. Blinding was maintained until the end of week 24. All doses of dorzagliatin 75 mg tablets and placebo tablets were administered orally twice daily, as single tablets.
EFFICACY Endpoints
The primary efficacy endpoint was the change in the HbA1c level from baseline to week 24. Key secondary efficacy endpoints included the changes in the 2-hour postprandial glucose level, fasting plasma glucose level from baseline to week 24, and the HbA1c level at each visit (except week 24); the HbA1c response rate (the percentage of patients who reached a HbA1c level of less than 7.0%) at week 24. Additional efficacy endpoints included the change in the homeostasis model assessment 2-β (an index for β-cell function) as well as the homeostasis model assessment 2 for insulin resistance (IR) from baseline. A full list of other efficacy endpoints is provided in the statistical analysis plan as the supplemental material.
SAFETY ENDPOINTS
Safety assessments were completed at every study visit. The blood and urine were sampled at each visit. Adverse events, serious adverse events were assessed throughout the trial (definitions are provided in the protocol as a supplemental material). Hypoglycemic episodes were classified according to the American Diabetes Association definitions (see the protocol provided as a supplemental material). Vital signs and clinical laboratory test results were assessed, and physical examinations were performed.
TRIAL Oversight
The trial was conducted in accordance with the principles of Declaration of Helsinki, Good Clinical Practice guidelines, and laws and regulations in China. The study protocol was amended once during study enrollment, and the important changes to methods after trial commencement and reasons were summarized in the supplemental material. The trial protocol and amendments were approved by the local ethics committees of all study sites. All patients provided written informed consent before trial entry. The trial was also conducted in accordance with the Chinese Diabetes Society guidelines, which require physicians to educate and strictly enforce improved exercise and dietary control as well as self-monitoring of blood glucose (at least 2 times per week), in treating type 2 diabetes patients.
Statistical Analyses
We hypothesized that dorzagliatin would show superiority to placebo in the decrease of HbA1c level in patients after 24-week treatment. For the primary endpoint of the change from baseline in HbA1c level at week 24, we calculated that a total sample size of 750 patients would provide the trial with 95.4% power to detect a difference of 0.4 percentage points between the dorzagliatin plus metformin group and the placebo plus metformin group in a 1:1 ratio of allocation at a 2-sided significance level of 0.05, assuming a standard deviation (SD) of 1.5 percentage points. The full analysis set included all randomized patients, who took at least one dose of study drugs and had at least one post-treatment measurement of the primary endpoint during double-blind treatment period. The safety set included all randomized patients, who took at least one dose of study drugs. Since this trial had only one confirmatory hypothesis test, i.e. the test of null hypothesis of no difference in the primary endpoint between dorzagliatin plus metformin and placebo plus metformin, there was no adjustment for multiplicity.
The primary analysis method for the primary efficacy endpoint was in the full analysis set using a mixed model for repeated measures without missing value imputation, which included treatment group, scheduled visit, interaction of treatment group with scheduled visit, pooled site, duration of diabetes (≤3 years or >3 years) and HbA1c baseline value as fixed effects. In the mixed model for repeated measures, data collected after initiation of prohibited antidiabetic medications (the amount and time of taking were reviewed in blind-data-review meeting and open-data-review meeting) were handled as missing data. The least-squares means of each treatment group, the estimated treatment difference between dorzagliatin plus metformin and placebo plus metformin and its 95% confidence interval (CI) were calculated. A sensitivity analysis was performed with the primary efficacy endpoint in the full analysis set using an analysis of covariance model with factors of treatment group, pooled site, duration of diabetes (≤3 years or >3 years) and HbA1c baseline value. In the analysis of covariance model, missing values were imputed using the method of last observation carried forward, which was applied after excluding data collected after initiation of prohibited antidiabetic medications. Another sensitivity analysis was performed with the primary efficacy endpoint using the same mixed model for repeated measures in the per-protocol set. The missing data of the primary efficacy endpoint due to the coronavirus disease epidemic were handled with the methods detailed in the statistical analysis plan and then a corresponding sensitivity analysis was carried out using the same method as the primary analysis.
The secondary efficacy endpoints including changes from baseline in 2-hour postprandial glucose, fasting plasma glucose levels at week 24, and the HbA1c level at each visit (except week 24) were assessed using the same mixed model for repeated measures for the primary endpoint. Another secondary efficacy endpoint of the HbA1c response rate (percentage of patients who reached a HbA1c level of less than 7.0%) was estimated based on the data imputed by last observation carried forward approach in the full analysis set. Odds ratio and 95% confidence interval between two treatment groups were estimated using the logistic regression model with factors of treatment group, pooled site, interaction of treatment group with pooled site (interaction effect removed from the model if not significant at a 2-sided alpha level of 0.1), duration of diabetes (≤3 years or >3 years) and baseline HbA1c level. For other efficacy endpoints, such as the changes from baseline in the homeostasis model assessment 2-β and homeostasis model assessment 2-insulin resistance were analyzed in the full analysis set using the same analysis of covariance model as described above.
The incidence of treatment-emergent adverse events that occurred between the first intake of double-blind study medications and the 7th day after the last dose of study medications was summarized by treatment group and compared between two treatment groups. The incidence of hypoglycemic events was also summarized by treatment group and compared between treatment groups. Additional details regarding the statistical analysis are provided in the statistical analysis plan as a supplemental material.